Cyclacel Pharmaceuticals Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Spiro Rombotis
Chief Executive Officer (CEO)
US$661.0k
Compensación total
| Porcentaje del salario del CEO | 84.7% |
| Permanencia del CEO | 26.8yrs |
| Participación del CEO | 2.2% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 7.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely
Aug 17
Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis
Aug 07Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?
Apr 15Cyclacel CEO Spiro Rombotis - Addressing Cancer Resistance (Video)
Oct 04Cyclacel issues key business objectives for 2021
Jan 11Cyclacel Pharma inks securities purchase agreement for $7M
Dec 22Cyclacel Pharmaceuticals EPS misses by $1.74
Nov 11Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$661k | US$560k | -US$23m |
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$24m |
| Mar 31 2023 | n/a | n/a | -US$23m |
| Dec 31 2022 | US$764k | US$546k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$20m |
| Dec 31 2021 | US$1m | US$531k | -US$19m |
| Sep 30 2021 | n/a | n/a | -US$20m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$1m | US$531k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$8m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$1m | US$531k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$8m |
| Jun 30 2019 | n/a | n/a | -US$8m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$753k | US$531k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$14m |
| Mar 31 2018 | n/a | n/a | -US$15m |
| Dec 31 2017 | US$776k | US$531k | -US$15m |
Compensación vs. Mercado: La compensación total ($USD661.05K) de Spiro está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Spiro ha sido consistente con los resultados de la empresa en el último año.
CEO
Spiro Rombotis (64 yo)
26.8yrs
Permanencia
US$661,049
Compensación
Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Pharmaceuticals, Inc. (formerly known as Cyclacel Group plc)) since August 1997 and has been its Founding C...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 18.2yrs | US$661.05k | 2.25% $ 59.3k | |
| Executive VP of Finance | 18.2yrs | US$352.62k | 1.22% $ 32.1k | |
| Interim Chief Medical Officer & Director | 3.4yrs | US$101.00k | 1.27% $ 33.4k | |
| Independent Director | 9.7yrs | US$116.50k | 0.32% $ 8.3k | |
| Independent Chairman | 18.2yrs | US$155.50k | 0.31% $ 8.2k | |
| Independent Director | 3.5yrs | US$95.49k | 0.32% $ 8.4k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Vice Chairman | 5.7yrs | US$130.75k | 0.31% $ 8.1k | |
| Independent Director | 1.9yrs | US$85.49k | 0.18% $ 4.7k |
7.7yrs
Permanencia media
67yo
Promedio de edad
Junta con experiencia: La junta directiva de CYCC se considera experimentada (7.6 años de antigüedad promedio).